Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by ST Germain D J Co. Inc.

ST Germain D J Co. Inc. lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 95,730 shares of the medical equipment provider’s stock after buying an additional 4,218 shares during the period. ST Germain D J Co. Inc.’s holdings in Zimmer Biomet were worth $10,334,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. M&G Plc acquired a new stake in shares of Zimmer Biomet during the first quarter valued at about $7,397,000. AMF Tjanstepension AB purchased a new stake in Zimmer Biomet in the first quarter valued at approximately $30,300,000. Factory Mutual Insurance Co. acquired a new position in Zimmer Biomet during the first quarter worth $10,862,000. Gradient Investments LLC boosted its position in shares of Zimmer Biomet by 17.3% during the second quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider’s stock worth $14,147,000 after buying an additional 19,224 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of Zimmer Biomet by 7.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 229,233 shares of the medical equipment provider’s stock worth $30,265,000 after buying an additional 15,548 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 1.3 %

Zimmer Biomet stock traded up $1.36 during mid-day trading on Friday, hitting $106.31. The company had a trading volume of 1,081,686 shares, compared to its average volume of 1,484,901. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90. The business has a fifty day moving average of $108.11 and a 200 day moving average of $112.42. The stock has a market cap of $21.87 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 1.93 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping the consensus estimate of $1.99 by $0.02. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. Zimmer Biomet’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period last year, the business earned $1.82 EPS. On average, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 7.98 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.90%. Zimmer Biomet’s dividend payout ratio is presently 20.78%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Wolfe Research began coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They set a “peer perform” rating on the stock. Canaccord Genuity Group reduced their price target on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th. Oppenheimer lowered their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, September 17th. Finally, UBS Group decreased their price target on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $123.74.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.